Reviewer's report
Title:Efficacy of omeprazole, famotidine, mosapride and teprenone in patients
with upper gastrointestinal symptoms: an omeprazole-controlled randomized
study (J-FOCUS)
Version: 2Date:9 September 2011
Reviewer: Tiberiu Hershcovici
Reviewer's report:
This is an interesting study performed in Japan.Although the study's metodology
is correct, the question adrressed by the study is irrelevant to the daily
gastroenterologist. No one will treat today a patient aged more than 45 years with
upper GI symptoms (non-reflux )without a previous investigation. Although PPI
treatment is well known to be efficacious for the treatment of these dyspeptic
symptoms (and more eficacious than H2RA), its use can be even dangerous in
some population groups (such as Japanese people) with high incidence of
gastric cancer.Accordingly, the conclusions of this study can give a sense of
false security to some physicians to use PPI as first line treatment of patients
with uninvestigated upper GI symptoms.Although PPI is well known as first line
treatment for reflux symptoms, its use for uninvestigated dyspepsia is
unacceptable.
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
Reviewer's report
Title:Efficacy of omeprazole, famotidine, mosapride and teprenone in patients
with upper gastrointestinal symptoms: an omeprazole-controlled randomized
study (J-FOCUS)
Version: 2Date:9 September 2011
Reviewer: Tiberiu Hershcovici
Reviewer's report:
This is an interesting study performed in Japan.Although the study's metodology
is correct, the question adrressed by the study is irrelevant to the daily
gastroenterologist. No one will treat today a patient aged more than 45 years with
upper GI symptoms (non-reflux )without a previous investigation. Although PPI
treatment is well known to be efficacious for the treatment of these dyspeptic
symptoms (and more eficacious than H2RA), its use can be even dangerous in
some population groups (such as Japanese people) with high incidence of
gastric cancer.Accordingly, the conclusions of this study can give a sense of
false security to some physicians to use PPI as first line treatment of patients
with uninvestigated upper GI symptoms.Although PPI is well known as first line
treatment for reflux symptoms, its use for uninvestigated dyspepsia is
unacceptable.
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
Please review this paper.
user
Reviewer's report
Title:Efficacy of omeprazole, famotidine, mosapride and teprenone in patients
with upper gastrointestinal symptoms: an omeprazole-controlled randomized
study (J-FOCUS)
Version: 2Date:9 September 2011
Reviewer: Tiberiu Hershcovici
Reviewer's report:
This is an interesting study performed in Japan.Although the study's metodology
is correct, the question adrressed by the study is irrelevant to the daily
gastroenterologist. No one will treat today a patient aged more than 45 years with
upper GI symptoms (non-reflux )without a previous investigation. Although PPI
treatment is well known to be efficacious for the treatment of these dyspeptic
symptoms (and more eficacious than H2RA), its use can be even dangerous in
some population groups (such as Japanese people) with high incidence of
gastric cancer.Accordingly, the conclusions of this study can give a sense of
false security to some physicians to use PPI as first line treatment of patients
with uninvestigated upper GI symptoms.Although PPI is well known as first line
treatment for reflux symptoms, its use for uninvestigated dyspepsia is
unacceptable.
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
assistant